- Home
- JZXN vs PMCB Comparison
JZXN vs PMCB Comparison
Compare JZXN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- PMCB
- Stock Information
- Founded
- JZXN 2017
- PMCB 1996
- Country
- JZXN China
- PMCB United States
- Employees
- JZXN N/A
- PMCB N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JZXN Consumer Discretionary
- PMCB Health Care
- Exchange
- JZXN Nasdaq
- PMCB Nasdaq
- Market Cap
- JZXN 15.3M
- PMCB 15.8M
- IPO Year
- JZXN 2021
- PMCB N/A
- Fundamental
- Price
- JZXN $1.44
- PMCB $1.77
- Analyst Decision
- JZXN
- PMCB
- Analyst Count
- JZXN 0
- PMCB 0
- Target Price
- JZXN N/A
- PMCB N/A
- AVG Volume (30 Days)
- JZXN 46.3K
- PMCB 37.6K
- Earning Date
- JZXN 10-15-2024
- PMCB 09-17-2024
- Dividend Yield
- JZXN N/A
- PMCB N/A
- EPS Growth
- JZXN N/A
- PMCB N/A
- EPS
- JZXN N/A
- PMCB 0.54
- Revenue
- JZXN $7,597,423.00
- PMCB N/A
- Revenue This Year
- JZXN N/A
- PMCB N/A
- Revenue Next Year
- JZXN N/A
- PMCB N/A
- P/E Ratio
- JZXN N/A
- PMCB $3.31
- Revenue Growth
- JZXN 81.94
- PMCB N/A
- 52 Week Low
- JZXN $1.00
- PMCB $1.39
- 52 Week High
- JZXN $67.60
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- JZXN 43.08
- PMCB 48.90
- Support Level
- JZXN $1.42
- PMCB $1.72
- Resistance Level
- JZXN $1.90
- PMCB $2.06
- Average True Range (ATR)
- JZXN 0.15
- PMCB 0.28
- MACD
- JZXN 0.04
- PMCB -0.00
- Stochastic Oscillator
- JZXN 9.80
- PMCB 38.24
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.